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Postmarketing nutrivigilance safety profile: a line  
of dietary food supplements containing red yeast rice 
for dyslipidemia
Maciej Banach1,2,3, Niki Katsiki4, Gustavs Latkovskis5,6, Manfredi Rizzo7, Daniel Pella8,  
Peter E. Penson9,10, Zeljko Reiner11, Arrigo FG Cicero12,13
A b s t r a c t
Introduction: In the absence of a  European standardized postmarketing 
food supplement surveillance system (nutrivigilance), some member states 
and companies have developed their own approaches to monitoring poten-
tial adverse reactions to secure a  high level of product safety. This paper 
describes the use of a nutrivigilance system in monitoring the incidence of 
spontaneously reported suspected adverse reactions associated with food 
supplements containing red yeast rice (RYR).
Material and methods: We report the data from a widely used product mar-
keted under the trademark Armolipid/Armolipid Plus. Postmarketing infor-
mation was collected in a  voluntary nutrivigilance system established by 
the manufacturing company (Meda Pharma SpA, a Viatris Company, Monza, 
Italy). From 1st October 2004 to 31st December 2019, this system captured 
cases of suspected adverse reactions spontaneously reported by consumers, 
healthcare professionals, health authorities, regardless of causality. 
Results: The total number of case reports received mentioning the RYR food 
supplement product line was 542, in which 855 adverse events (AEs) were 
reported. The total reporting rate of AEs was estimated to be 0.037% of 
2,287,449 exposed consumers. Of the 542 cases, 21 (0.0009% of exposed 
consumers) included suspected serious adverse events (SAEs). After careful 
investigation, 6 cases (0.0003% of consumers exposed) and 6 AEs were as-
sessed by the manufacturer as serious and potentially related to exposure 
to the above-mentioned RYR-based nutraceutical. 
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Conclusions: This nutrivigilance-derived data analysis clearly demonstrates a low prevalence of suspected 
adverse events associated with the red yeast rice product line. Consumer safety of food supplements could 
be generally improved by raising awareness of the importance of following the indications and warnings 
detailed in a food supplement’s labeling. 
Key words: adverse event, dyslipidaemia, nutrivigilance, red yeast rice, supplement.
Introduction
Elevated serum low-density lipoprotein choles-
terol (LDL-C) is an established risk factor for ath-
erosclerotic cardiovascular (CV) disease [1–3]. For 
the general population and those at increased CV 
risk, decreasing the LDL-C by dietary adjustment 
represents the primary method of CV risk reduc-
tion and therefore deserves special emphasis in 
the evaluation of lifestyle changes [2]. Dietary ad-
justments, however, achieve a reduction of LDL-C 
which is insufficient to reach the recommended 
LDL-C levels in most cases [4].
To this end, the European Society of Cardiolo-
gy (ESC)/European Atherosclerosis Society (EAS) 
guidelines 2019 recommend lifestyle interven-
tions, which include not only dietary adjustments 
but also the use of functional foods [2]. A nutra-
ceutical ingredient, red yeast rice (RYR), has the 
higher-level (grade A) recommendation because 
of its clinically relevant impact on improving li-
poprotein profiles [2]. The relevance of RYR was 
discussed in the ESC/EAS guidelines in 2011, to-
gether with a recommendation supporting its use. 
This guidance was reconfirmed in the 2019 up-
date [2, 5]. Its important role in the lipid-lower-
ing management was also confirmed in the first 
nutraceuticals guidelines of the International Lipid 
Expert Panel (ILEP) [6, 7]. 
For individuals who fall into the low-to-mod-
erate CV risk category, changes in lifestyle may 
be indicated, whereas statin therapy may not [8]. 
The guidelines also state that RYR may be consid-
ered for subjects with elevated cholesterol levels 
for whom statin therapy is not yet indicated [2]. 
The ESC/EAS guidelines note that clinically rele-
vant cholesterol decreases were reported with RYR 
amounts containing monacolin K doses of 2.5 mg/
day to 10 mg/day [2]. 
Several RYR-based supplements are available 
on the market, some contain only RYR, whereas 
other products contain additional ingredients [8] 
such as policosanol [9], berberine [9–11], co-en-
zyme Q
10 (CoQ10) [12–14].
In the European Food Safety Authority’s (EFSA’s) 
assessment of RYR use (2018), decisions were 
based on selected studies which evaluated sup-
plementation with mono-ingredient products [15]. 
The EFSA observed that most reported AEs were 
musculoskeletal in nature, followed by fatigue, 
pain, and gastrointestinal (GI) symptoms [15]. 
Hepatic AEs were also observed to occur in a sig-
nificant number of patients receiving RYR supple-
mentation, according to the EFSA [15]. The EFSA 
considered the lactone form of monacolin K to be 
identical to lovastatin and states that RYR food 
supplement intake could result in an exposure 
to monacolin K levels comparable with thera-
peutic doses of lovastatin [15]. However, taking 
into account the selectivity of the data sources 
used in the report, lack of complete data on the 
quality production, and lack of rechallenge in the 
included studies, it was difficult to confirm the 
causality of the reported AEs with the RYR sup-
plementation [16]. 
A  2017 analysis of 28 brands of RYR supple-
ments available in the United States and the Eu-
ropean Union showed that 7% provided labeling 
advising against the concurrent use of statins and 
that monacolin K content was not included on 
any of the product labels [17]. In 2 of the analyzed 
products, monacolin K was undetectable, and 
across the brands that did contain monacolin K, 
the dose per 1200 mg of RYR ranged from 0.09 
mg to 5.48 mg [17]. Moreover, the lack of harmo-
nization among nutrivigilance processes and pro-
cedures for food supplement products at the EU 
level further complicates the EU regulatory land-
scape of food supplements. As a consequence, the 
reporting requirements of supplement associated 
AEs, if they exist, may differ from one EU member 
state to another. 
On the contrary, at least 3 controlled trials have 
shown that RYR is well tolerated [18–20]. In anoth-
er study, no AEs were reported following 10 weeks, 
during which 50 patients with dyslipidemia were 
randomized to a  combination food supplement 
containing monacolin K (3 mg) or placebo [21]. 
In a 2012 study, 64 hyperlipidemic patients were 
randomized to a  combination food supplement 
containing monacolin K (3 mg) or placebo for 
18 weeks, after which no hepatic or renal chang-
es and no serious AEs (SAEs) were reported [22]. 
In studies that involved a  6- to 48-week course 
of Armolipid enhanced RYR supplement, 2.2% of 
the 1600 treated subjects reported only nonseri-
ous AEs, and no life-threatening events were re-
ported. The rates of subjects reporting AEs were 
not different from placebo [9]. Finally, in a recent 
meta-analysis that included more than 8500 sub-
jects, RYR supplementation was not associated 
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with an increased risk for muscular or non-mus-
cular AEs (which have been observed with statin 
use); the authors additionally observed significant 
reduction of SAEs [23].
Based on the abovementioned inconsistent 
data on RYR safety, the aim of our study was to 
evaluate the safety of a  line of RYR food supple-
ments (Meda Pharma; a Viatris Company, Monza, 
Italy), available since October 2004, in the post-
marketing real-life setting via the company’s nu-
trivigilance and safety data collection methods. 
Material and methods
As an example of a  proactive approach, by 
companies in Europe, to report post-marketing in-
formation about safety, we report the data from 
a widely used product, marketed since 1st October 
2004, under the trademark Armolipid and Armo-
lipid Plus, manufactured by Meda Pharma, a Via-
tris Company (Monza, Italy). Evaluated products 
were well characterized from a quality perspective 
(including citrinin content), have customer-friend-
ly labeling, and have comparable formulations 
(RYR content), allowing the analysis and compar-
ison of postmarketing data while avoiding biases 
stemming from different contents in the formula-
tions. One tablet of the standard RYR supplement 
contains RYR (200 mg, the equivalent of mona-
colin K, 3 mg), folic acid (0.2 mg), CoQ
10 (2 mg), 
and astaxanthin (0.5 mg), and in some countries, 
policosanol (10 mg). One tablet of the enhanced 
RYR supplement contains Berberis aristata extract 
(588 mg, equivalent to berberine chloride 500 mg), 
RYR (200 mg, the equivalent of monacolin K, 
3 mg), policosanol (10 mg), folic acid (0.2 mg), 
CoQ
10 (2.0 mg), and astaxanthin (0.5 mg) [24]. 
A nutrivigilance process was used to monitor 
the reporting rate and nature of AEs suspected to 
be associated with the RYR. An AE was defined as 
“any untoward medical occurrence” in a consum-
er while using a food supplement, even when an 
apparent causal relationship does not necessarily 
exist. The causal relationship might already have 
been suspected by the reporter or by the com-
plaining consumer; nevertheless, a  causality as-
sessment was performed for all the case reports 
later in the company’s nutrivigilance process. The 
AEs described on the food supplement label avail-
able to the consumer were considered to be “ex-
pected” or “labeled”. Serious AEs were defined 
as: death; a life-threatening event; an event that 
required or prolonged hospitalization; or one that 
resulted in a significantly or persistently incapac-
itated or disabled state, a birth defect, or a con-
genital abnormality. Severe events, based on the 
definition of the European Medicines Agency 
(EMA) [25], were not considered synonymous 
with SAEs.
Since product launch in 2004 an internal nutriv-
igilance database was developed, with increasing 
global pharmacovigilance-like systems and pro-
cedures. The database was validated and imple-
mented to record case reports from worldwide 
sources. Spontaneous reports originating from 
healthcare professionals (HCPs), consumers or 
health authorities were verified as original source 
reports (i.e., not duplicates), and AEs were coded 
according to the standard Medical Dictionary for 
Regulatory Activities. Collected reports included 
those, in which a correlation between an AE and 
a food supplement was suspected by the reporter 
and was later evaluated for causal association (af-
ter entry into the database). Additional collected 
information included reports of deficient efficacy, 
misuse (e.g., divergence from label instructions), 
and contraindicated use during pregnancy or 
breastfeeding. The World Health Organization-Up-
psala Monitoring Centre system was selected to 
guide the evaluation of causality via parameters 
including time to onset, clinical plausibility, de-
challenge, and rechallenge [24]. Cumulative data 
reported over a 16-year period (from 1st October 
2004 through December 31, 2019) were carefully 
evaluated and correlated with extrapolated con-
sumer exposure to the RYR food supplement line. 
Results
An estimated total of 2,287,449 consumers 
from 16 countries (Italy, Spain, Ireland, Germany, 
Greece, Belgium, Luxemburg, Malta, Hungary, Po-
land, Russia, Belarus, Ukraine, Thailand, Singapore 
and Taiwan) took the recommended 1 tablet per 
day of the Armolipid RYR-based nutraceutical con-
tinuously for 1 year. This number was calculated 
from an estimated annual exposure based on the 
834,918,819 tablets manufactured in the Europe-
an Union from the time of initial marketing in Oc-
tober 2004 through December 31, 2019, and the 
recommended dose of 1 tablet per day. The data-
base accumulated 542 spontaneous case reports, 
estimated to equate to 542 consumers, with 855 
suspected AEs. Consumers who reported ≥ 1 AEs 
with respect to use of the RYR were 0.0237% of 
the 1-year exposed consumers.
The percentage of any-cause AEs in associa-
tion with RYR was 0.0374% of the 1-year exposed 
consumers (Table I). The majority of reported AEs 
were nonserious, with a total of 829 in 855 sus-
pected AEs, which was 97% of all the AEs and 
comprised a 0.0362% prevalence in the exposed 
consumers. A total of 26 initial SAEs were record-
ed, received in 21 case reports with ≥ 1 SAEs. 
The 21 cases related to 21 different consumers, 
comprising 0.0009% of the exposed consumers. 
Based on the 26 SAEs, a SAE prevalence equal to 
0.0011% of exposed consumers was estimated. 
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Upon further evaluation, only 6 of the 26 SAEs 
qualified as serious reactions (fulfilling the estab-
lished definition) and reactions, in which the food 
supplement could not be excluded as the cause. 
This resulted in a SAE frequency of 0.0003% of ex-
posed consumers.  
GI AEs were the most commonly reported 
(293/855), constituting 34.3% of the AEs and 
0.0128% of the RYR-based nutraceutical-exposed 
consumers. GI-related events included in the 
21 case reports of SAEs included reports of diarrhea, 
vomiting, nausea with vomiting, lipedema, and 
1 of intestinal obstruction that was later suspected 
to be constipation, as it did not require hospital-
ization and resolved with laxative treatment. The 
seriousness of the vomiting/nausea reports were 
assessed as questionable, as was the causality of 
the lipedema. None of the GI events reported as 
serious were confirmed as serious or as resulting 
only from exposure to this nutraceutical.
Reports of musculoskeletal disorder AEs fol-
lowed those with GI features in frequency, com-
prising 148 of the 855, or 17.3% of the AEs, and 
0.0064% of the RYR-exposed consumers. Of the 
musculoskeletal AEs, 2 were serious in nature 
but were associated with noncompliance with 
the recommendations on the supplement’s label. 
Rhabdomyolysis was reported in 2 consumers 
(1 involved hospitalization), but in both cases the 
product’s label warnings were not followed. In the 
first of these 2 cases, an elderly woman who was 
taking sertraline and rosuvastatin started the en-
hanced RYR supplement without seeking medical 
advice. She developed rhabdomyolysis but re-
covered after discontinuing the RYR supplement 
and rosuvastatin. The enhanced RYR supplement 
label advises against its concomitant use with 
other hypolipidemic products. The second case 
involved an unknown-gendered consumer who 
developed rhabdomyolysis and required hospital-
ization after having started taking the enhanced 
RYR supplement without prior medical consulta-
tion. This subject had a history of rhabdomyoly-
sis in response to simvastatin, and the enhanced 
RYR supplement label advises consumers to con-
sult a physician to decrease the risk for musculo-
skeletal AEs. Therefore, no case of rhabdomyoly-
sis without concomitant or prior statin exposure 
was detected.
Hepatic AEs, including reports of transaminase 
alterations, occurred in 26 of the 855 reported AEs, 
constituting 3.0% of the AEs and a  frequency of 
0.0011% in the RYR-exposed consumers. Hepatic 
SAEs occurred in 7 patients who were diagnosed 
Table I. Armolipid line Red Yeast Rice–Exposed Consumers and Adverse Events
Parameter Number Frequency in exposed 
consumers (%)
AEs, total 855 0.0374
Consumers reporting ≥ 1 AEs 542 0.0237
Nonserious AEs 829 0.0362
AEs reported as serious by reporter  26 0.0011
Consumers reporting an SAE 21 0.0009
Consumers reporting SAEs confirmed as serious and unable to exclude 
causal relationship 
6 0.0003
GI AEs, total 293      0.0128
GI SAEs (as reported) 5 0.0002
GI SAEs confirmed as serious and unable to exclude causal relationship 0 0.0000
Musculoskeletal AEs, total 148 0.0064
Musculoskeletal SAEs (as reported) 2 0.0001
Musculoskeletal SAEs confirmed as serious and unable to exclude causal 
relationship
1 0.0000
Hepatic AEs (including transaminase alteration), total 26 0.0011
Hepatic SAEs (as reported) 9 0.0004
Hepatic SAEs confirmed as serious and unable to exclude causal 
relationship
3 0.0001
Other SOC AEs, total 388 0.0170
Other SOC SAEs 5 0.0002
Other SOC SAEs confirmed as serious and unable to exclude causal 
relationship
2 0.0001
Consumers exposed 2 287 449
AE – adverse event, GI – gastrointestinal, SADR – serious adverse reaction, SOC – system organ class.
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with serious hepatitis. Causality for one of these 
cases, wherein the subject had an unremarkable 
medical history and had also been taking ateno-
lol, levothyroxine, and potassium canrenoate, was 
considered probable by the reporter. In another 
case, the causality was considered by the report-
ing physician to be more likely associated with the 
amoxicillin/clavulanic acid antibiotic (with liver in-
jury as a known adverse drug reaction) also taken 
by the consumer. In the other SAE reports, vari-
ous patterns of presentation (i.e., hepatocellular, 
cholestatic) were mentioned and the symptoms 
resolved spontaneously or after treatments of glu-
tathione, cortisone, or ursodeoxycholic acid. The 
latency range in these reports varied widely, from 
1 month to 2 years following RYR supplement in-
take, and the range of causality included probable 
(in 1 case), possible (in 2 cases), and unlikely (in 
2 cases).
The frequency of AEs was calculated, start-
ing from 1st October 2004 through December 
31, 2017, then up to December 31, 2019, as 
was done for the data previously discussed. Up 
to 2017, consumers of the RYR supplement to-
talled 1,613,053, and 300 case reports were re-
ceived mentioning 501 AEs, of which 26 were 
reported as SAEs by 21 consumers. These data 
were also shared with the EFSA and with the 
European Commission Directorate-General for 
Health and Food Safety as comments to the sci-
entific opinion drafted and published by the EFSA 
on August 31, 2018. Until the end of 2018, ex-
posed consumers increased to 1,912,475 and 
case reports increased to 442, for a  total of 
705 AEs reported. Still, 26 AEs were reported as 
serious by 21 consumers. Through the end of 
2019, exposed consumers totalled 2,287,449, 
with 542 case reports mentioning 855 AEs. Again, 
26 AEs were reported as serious by 21 consum-
ers. Despite the increase in case reports, the num-
ber of reports mentioning SAEs has remained 
unchanged over the past 3 years. Expanding 
the evaluation up to the past 5 years (Figure 1) 
showed increases in the number of consumers 
exposed and in reported AEs. This could be due to 
increased awareness among HCPs and consumers 
about the importance of reporting suspected AEs, 
and possibly as a consequence of the EFSA’s pub-
lished opinion. Nocebo, or more correctly drucebo 
effect, cannot be also ruled out as a reason of ob-
served AEs [26, 27]. Some factors that also may 
influence whether an event is reported include 
length of time since marketing, market share of 
the suspect product, publicity of the product, and 
regulatory actions. Also, the mentioned nutriv-
igilance system showed improved effectiveness 
over time, with Company’s employees trained to 
systematically forward any case report to the cen-
tral office of nutrivigilance. 
Discussion
Postmarketing nutrivigilance data showed 
a  high tolerability of the RYR. The percentage 
of any-cause AE reported when taking RYR was 
0.0374% of the 1-year-exposed consumers. The 
majority of reported AEs were nonserious, with 
a total of 829 of 855, which was 97% of all AEs 
and 0.0362% of the exposed consumers. Of the 
21 case reports (which comprised 0.0009% of the 
accumulated exposed consumers) with ≥ 1 SAEs, 
6 qualified as confirmed serious in the nature of 
the AE and wherein the RYR could not be excluded 
as the cause, an SAE frequency of 0.0003% of the 
exposed consumers. The incidence of AEs reported 
with the RYR supplement product line were rare to 
very rare, whereas they are rare to common with 
lovastatin [8].
 Up to 2015 Up to 2016 Up to 2017 Up to 2018 Up to 2019
 Consumer exposed (millions)           AE, total (per millions exposure)
 Non serious AE (per million exposure)           AE reported as serious by reporter (per million exposure)
 AE confirmed as serious as AND whose causality with product cannot be excluded (per million exposure)
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The unchanged number of SAEs over the past 
3 years demonstrates that the RYR line is well tol-
erated, with a favorable safety profile when used 
in line with the product’s labeling. The Armolipid 
RYR line’s consumer package leaflets include rec-
ommendations regarding dosage, contraindicated 
conditions (including the concurrent use of drugs 
for dyslipidemia), and HCP consultation to avoid 
potential musculoskeletal disorder risk.
Based on the best practices of some European 
member states (e.g. in Italy, France, and Belgium), 
the Armolipid RYR has a  standardized minimum 
global label warning that can be further extend-
ed based on local authorities’ requirements: “Do 
not exceed the recommended daily dose. Keep out 
of the reach of young children. Do not use during 
pregnancy, lactation or in combination with hypo-
lipidemic drugs. It is advised to consult a physi-
cian for the product use. Food supplements must 
not be considered as substitutes of a varied, bal-
anced diet and a  healthy lifestyle. Gastrointesti-
nal disorders and muscular pain may occur taking 
(the Armolipid RYR), mainly in subjects intolerant 
to statins. A doctor should be consulted if muscu-
lar pain occurs”.
This evaluation about nutrivigilance had some 
limitations and strengths. One of the limitations 
was the inclusion of an RYR product line with 
a dosage of 3 mg of monacolin K; no other dos-
ages have been monitored, as they do not re-
port regular nutrivigilance data. These methods 
of reporting cannot be obviously compared with 
the pharmacovigilance methods, which are im-
plemented for drugs. However, since no vigilance 
measures/reporting are required from Companies 
under the current regulations for food supple-
ments/nutraceuticals, we consider this kind of 
voluntary reporting a good practice, to be widely 
recommended for monitoring of potential adverse 
events. 
A surveillance assessment reported a collection 
of suspected AEs from the Italian Surveillance 
System of Natural Health Products regarding the 
potential signs of liver injuries and myopathies 
[16]. This assessment can only be considered 
qualitatively. In addition, the authors acknowl-
edged the data analyzed had a number of limita-
tions, primarily the unavailability of sales data for 
RYR food supplements because of their regulatory 
status (i.e., not reimbursed) [16]. Consequently, 
such data were not captured in the standard ad-
ministrative databases to contextualize the num-
ber of reported AEs with participant exposure. 
All supplements that were assessed, except one, 
contained other natural components than RYR. 
According to the surveillance authors, the case 
reports contained limited documentation, lacking 
information on underlying diseases and suspect-
ed concomitant medications. Of importance, such 
information reported spontaneously from these 
databases cannot be used to determine incidence 
rates of AEs [16].
The present results are therefore relevant in 
demonstrating the importance of a nutrivigilance 
system applied to food supplements when evalu-
ating the safety of products, once product quality 
and labeling are established and do not introduce 
bias. Scientific societies recommend HCPs select 
products from manufacturers that follow high-lev-
el, industry-quality standards [10]. In addition, 
HCPs are encouraged to report AEs to companies 
[8]. Companies with standardized products and 
nutrivigilance systems in place can capture and 
analyze AE trends for their own products and con-
firm the products’ labeling or evaluate the need 
for additional warnings to increase consumer 
awareness. 
In conclusion, the implementation of nutrivig-
ilance methods, together with high-quality stan-
dards, including control of contaminants, improve 
consumer safety. Moreover, correct labeling with 
clearly stated precautions is important for the 
availability of comprehensive information to con-
sumers. A  nutrivigilance system, capturing infor-
mation spontaneously reported from the markets, 
also allows manufacturer to confirm the safety of 
products. Based on the evaluation of the cumula-
tive safety data from the manufacturer’s nutrivig-
ilance database, the Armolipid family of RYR sup-
plements has demonstrated that it remains safe, 
and an effective support for LDL control, as expert 
guidelines recommend, when it is used according 
to the instructions on the product label. Compli-
ance with label and/or package leaflet warnings, 
as well as with healthcare provider (HCP) recom-
mendations, is essential to AE risk reduction, and 
the overall efficacy and safety of food supplement 
consumption.
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